Hayley M Sabol, MS

Research Program: Cancer Biology Faculty Rank: Graduate Assistant Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Physiology & Cell Biology

Cancer Research Interest

• Disease Site Focus: Multiple Myeloma
• Research Focus Area: Treatment
• Type of Research: Basic
• Research Keywords: Multiple myeloma, tumor microenvironment, dormancy, Notch signaling, bone
• Research Interest Statement: I am currently a 5th-year Ph.D. candidate at UAMS in the Graduate Program in Biomedical Sciences in the lab of Dr. Jesus Delgado-Calle. My long-term research goal is to study the cellular and molecular mechanisms of cancer to identify targetable molecules to improve clinical outcomes for cancer patients. My Ph.D. studies focus on developing and characterizing bone-targeted therapeutic approaches to treat multiple myeloma. Using in vitro, ex vivo, and in vivo approaches, I investigate the effect that a bone-targeted Notch inhibitor and an anti-Sclerostin antibody have on multiple myeloma tumor growth, dormancy, and bone disease.

Contact Information

• Email Address: HSABOL@UAMS.EDU

Active Grants

• NIH/Nat. Cancer Institute – F31CA284655
  “Targeting Notch3 for the treatment of multiple myeloma”
  Principal Investigator
  7/1/2023 – 6/30/2025

Recent Publications

• Anloague A, Sabol HM, Kaur J, [et al.]. Novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma. Haematologica. 2024. PMID: 39605211.
• Kaur J, Adhikari M, Sabol HM, [et al.]. Single-cell Transcriptomic Analysis Identifies Senescent Osteocytes that Trigger Bone Destruction in Breast Cancer Metastasis. Cancer research. 2024. PMID: 39312185. PMCID: PMC11611663.
• Sabol HM, Ashby C, Adhikari M, [et al.]. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024. PMID: 38385272. PMCID: PMC11290536.
• Marino S, Petrusca DN, Bishop RT, [et al., including Sabol HM]. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma. Haematologica. 2023. PMID: 37981834. PMCID: PMC11063840.
• Sabol HM, Amorim T, Ashby C, [et al.]. Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. Neoplasia (New York, N.Y.). 2022 28:100785. PMID: 35390742. PMCID: PMC8990177.
• Sabol HM, Ferrari AJ, Adhikari M, [et al.]. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity. Cancer research. 2021. PMID: 34348968. PMCID: PMC8488008.
• Sabol HM, Delgado-Calle J. The multifunctional role of Notch signaling in multiple myeloma. Journal of cancer metastasis and treatment. 2021 7. PMID: 34778567. PMCID: PMC8589324.